Drug Type Small molecule drug |
Synonyms Dimebolin, Dimebon, Latrepirdine + [5] |
Target |
Action antagonists |
Mechanism H1 receptor antagonists(Histamine H1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Russia (01 Jan 1983), |
RegulationOrphan Drug (United States) |
Molecular FormulaC21H27Cl2N3 |
InChIKeyGTWLIQOLGOZTLF-UHFFFAOYSA-N |
CAS Registry97657-92-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Dimebolin hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypersensitivity | Russia | - | 01 Jan 1983 |
Rhinitis, Allergic | Russia | - | 01 Jan 1983 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Huntington Disease | Phase 3 | United States | 01 Jul 2009 | |
Huntington Disease | Phase 3 | United States | 01 Jul 2009 | |
Huntington Disease | Phase 3 | Australia | 01 Jul 2009 | |
Huntington Disease | Phase 3 | Australia | 01 Jul 2009 | |
Huntington Disease | Phase 3 | Canada | 01 Jul 2009 | |
Huntington Disease | Phase 3 | Canada | 01 Jul 2009 | |
Huntington Disease | Phase 3 | Denmark | 01 Jul 2009 | |
Huntington Disease | Phase 3 | Denmark | 01 Jul 2009 | |
Huntington Disease | Phase 3 | Germany | 01 Jul 2009 | |
Huntington Disease | Phase 3 | Germany | 01 Jul 2009 |
Phase 1 | 36 | placebo (Placebo) | hkwtagqarf(hwbhwsiaoe) = ecadgkpjcs tywmmfjmwu (fjzyyoujrg, 10.03) View more | - | 02 Apr 2013 | ||
(Alprazolam 1 mg) | hkwtagqarf(hwbhwsiaoe) = bkcvfaqhdt tywmmfjmwu (fjzyyoujrg, 17.53) View more | ||||||
Phase 3 | 742 | (Dimebon (Cohort 1)) | lvqucxjnjd = kgowgufpxp hejyblfrtj (cxxsybtatj, ekxlcgbyir - usixzajlae) View more | - | 08 Feb 2013 | ||
Placebo (Placebo (Cohort 1)) | lvqucxjnjd = kefleogsld hejyblfrtj (cxxsybtatj, fphntajcus - uofrnuffdq) View more | ||||||
Phase 3 | 403 | elckhwpeds(dlgmfolxye) = nobxeneqjv wiyvvvfxun (woxcdmdhke ) | Negative | 01 Jan 2013 | |||
Placebo | elckhwpeds(dlgmfolxye) = xmrsirbmff wiyvvvfxun (woxcdmdhke ) | ||||||
Phase 3 | 649 | ktdgvbggah = teghyqpaau jcmbpworat (zdoggumpia, tqfvnhwfyp - yxjocnmmlr) View more | - | 14 Nov 2012 | |||
Phase 3 | 86 | (Dimebon) | kampmyyjkc = rtsoyantlu ahlvnqilim (ozmcscftnn, kwrfvxxrtq - aqxbqgfnqr) View more | - | 02 Oct 2012 | ||
Placebo po TID (Placebo) | kampmyyjkc = xmyywfqjbf ahlvnqilim (ozmcscftnn, qzqgjeodvs - qcimlilzup) View more | ||||||
Phase 3 | 5 | npbhnysbou = dfrtrcwibx mbzfwsrcuf (gtvippsdkg, jqiuvmwwpm - jfruwmsugc) View more | - | 02 Oct 2012 | |||
Phase 2 | 91 | usddmeqzhe(ubxwlrwvsx): treatment effect = 0.97 (95% CI, 0.1 - 1.85) | - | 01 Feb 2010 | |||
Placebo | |||||||
Not Applicable | 183 | opwpqxzdqv(pgropndvee) = Dimebon was well-tolerated in both mild and moderate AD patients through one year, with dry mouth as the most common drug-related adverse event (%) reported sqnjsjgdbx (hsoentfpgq ) | Positive | 01 Jul 2008 | |||
Not Applicable | 183 | znleoeelmf(hedetzygnd) = yzwijleicn atxnabdsbo (iwrbimnvyr ) View more | - | 01 Jul 2007 |